Investigational drug · Phase 2
WEF-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "WEF-001"
First trial start
2025
Jul 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "WEF-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma
- Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
- Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
- Advanced Solid Tumors
- Advanced or Metastatic KRAS-mutant Tumor
Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "WEF-001" as an intervention, largest first.
Auricula Biosciences Inc.Industry
NCT07148128 · 110 participants (planned) · Start Jul 28, 2025 · Primary completion Jan 2028
Drug: WEF-001 · For: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma; Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer; Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer and 2 more
Sites: Dallas, Texas; San Antonio, Texas; Toronto, Canada · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.